Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
02:10am, Sunday, 04'th Jan 2026
Avidity Biosciences (NASDAQ: RNA - Get Free Report) and Galecto (NASDAQ: GLTO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies base
3 Potential Mid-Cap Biotech Buyout Targets In 2026
06:22pm, Wednesday, 03'rd Dec 2025
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
06:59pm, Monday, 01'st Dec 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
09:13am, Wednesday, 19'th Nov 2025
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
07:56pm, Monday, 10'th Nov 2025
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
04:05pm, Monday, 10'th Nov 2025
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
09:44am, Friday, 31'st Oct 2025
Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity.
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
11:08am, Thursday, 30'th Oct 2025
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharmaceutical Stocks To Keep An Eye On – October 28th
02:09am, Thursday, 30'th Oct 2025
Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock
Top Medical Stocks To Research – October 28th
02:09am, Thursday, 30'th Oct 2025
UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener
3 Investable Laggards In An Overbought Market
05:13pm, Tuesday, 28'th Oct 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
02:42pm, Tuesday, 28'th Oct 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right
MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Cl
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
11:16am, Tuesday, 28'th Oct 2025
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?
10:21am, Tuesday, 28'th Oct 2025
Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
